F. Kraeber-bodéré, Tumor Immunotargeting Using Innovative Radionuclides, International Journal of Molecular Sciences, vol.55, issue.2, pp.16-3932, 2015.
DOI : 10.2967/jnumed.113.122630

O. R. Pozzi and M. R. Zalutsky, Radiopharmaceutical Chemistry of Targeted Radiotherapeutics, Part 3: ??-Particle-Induced Radiolytic Effects on the Chemical Behavior of 211At, Journal of Nuclear Medicine, vol.48, issue.7, pp.48-1190, 2007.
DOI : 10.2967/jnumed.106.038505

F. Guérard, Unexpected behavior of the heaviest halogen astatine in the nucleophilic substitution of aryliodonium salts, Chem. Eur. J, pp.22-12332, 2016.

F. Guérard, Bifunctional aryliodonium salts for highly efficient radioiodination and astatination of antibodies, Bioorganic & Medicinal Chemistry, vol.25, issue.21, 2017.
DOI : 10.1016/j.bmc.2017.09.022

A. Hermann, R. Hoffmann, and N. W. Ashcroft, Condensed Astatine: Monatomic and Metallic, Physical Review Letters, vol.31, issue.11, pp.111-116404, 2013.
DOI : 10.1002/anie.201302742

D. Teze, Targeted radionuclide therapy with astatine-211: Oxidative dehalogenation of astatobenzoate conjugates, Scientific Reports, vol.90, issue.1, 2017.
DOI : 10.1063/1.456153
URL : https://hal.archives-ouvertes.fr/in2p3-01529705

M. R. Zalutsky, Clinical experience with alpha-particle emitting 211 At: treatment of recurrent brain tumor patients with 211 At-labeled chimeric antitenascin monoclonal antibody 81C6, J. Nucl. Med, pp.49-79, 2008.

H. Andersson, Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211 At-MX35 F(ab')2. A phase I study, J. Nucl. Med, pp.50-1153, 2009.

L. , «. Un, and . Sur, sont coordonnées par un comité éditorial mené par Jean-Pierre Foulon et Séverine Bléneau-Serdel (contact : bleneau@lactualitechimique.org) Elles sont regroupées et en téléchargement